Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows

Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows
Pittsburgh, PA (PRWEB) June 01, 2015 Note: Dr. Julian is available for interviews today on this new development in breast cancer prevention. A phase III trial funded by the National Institutes of Health suggests that postmenopausal women with ductal carcinoma in situ (DCIS) now have an additional tool for breast cancer treatment and prevention. ...